• Staphylococcus aureus
• abscess formation
• bioinformatics
• computational proteomics
• host−pathogen interface
• machine learning
• mass spectrometry
• microLESA
• proteomics
• spatially targeted proteomics

• Animals
• Mice
• Proteomics/methods
• Calcium
• Computational Biology/methods
• Multivariate Analysis
• Proteome/metabolism

• R01 AI069233 NIAID NIH HHS
• U54 DK134302 NIDDK NIH HHS
• U54 DK120058 NIDDK NIH HHS
• R01 AI145992 NIAID NIH HHS
• R01 AI138581 NIAID NIH HHS
• U54 EY032442 NEI NIH HHS
• R01 AI073843 NIAID NIH HHS
• T32 ES007028 NIEHS NIH HHS
• F32 AI157215 NIAID NIH HHS

• Biomarkers
• Heart Failure
• Hypertrophic cardiomyopathy

• Humans
• Prospective Studies
• Proteomics
• Cardiomyopathy, Hypertrophic/diagnosis
• Cardiomyopathy, Hypertrophic/genetics
• Death, Sudden, Cardiac
• Heart Failure/complications
• Risk Factors

• K24 AG036778 NIA NIH HHS
• K24 HL107643 NHLBI NIH HHS
• R01 HL157216 NHLBI NIH HHS
• UL1 TR001873 NCATS NIH HHS

• cardiovascular diseases
• epigenome
• genome
• gonadal steroid hormones
• metabolomics
• sex characteristics
• transcriptome

Psoriatic disease (PsD) is a spectrum of diseases that affect both skin [cutaneous psoriasis (PsC)] and musculoskeletal features [psoriatic arthritis (PsA)]. A considerable number of patients with PsC have asymptomatic synovio-entheseal inflammations, and approximately one-third of those eventually progress to PsA with an enigmatic mechanism. Published studies have shown that early interventions to the very early-stage PsA would effectively prevent substantial bone destructions or deformities, suggesting an unmet goal for exploring early PsA biomarkers. The emergence of proteomics technologies brings a complete view of all involved proteins in PsA transitions, offers a unique chance to map all potential peptides, and allows a direct head-to-head comparison of interaction pathways in PsC and PsA. This review summarized the latest development of proteomics technologies, highlighted its application in PsA biomarker discovery, and discussed the possible clinical detectable PsA risk factors in patients with PsC.

• biomarkers
• proteomics
• psoriasis
• psoriatic arthritis
• psoriatic disease

• Saudi Arabia
• awareness
• cardiovascular disease
• knowledge
• risk factors

• AERD
• Aspirin-exacerbated respiratory disease
• Chronic rhinosinusitis
• Polyps
• SNOT-20 GAV
• Samter’s triad
• Sex

Cardiovascular diseases (CVD) represent one of the biggest causes of death globally, and their prevalence, aetiology, and outcome are related to genetic, metabolic, and environmental factors, among which sex- and age-dependent differences may play a key role. Among CVD risk factors, platelet hyperactivity deserves particular mention, as it is involved in the pathophysiology of main cardiovascular events (including stroke, myocardial infarction, and peripheral vascular injury) and is closely related to sex/age differences. Several determinants (e.g., hormonal status and traditional cardiovascular risk factors), together with platelet-related factors (e.g., plasma membrane composition, receptor signaling, and platelet-derived microparticles) can elucidate sex-related disparity in platelet functionality and CVD onset and outcome, especially in relation to efficacy of current primary and secondary interventional strategies. Here, we examined the state of the art concerning sex differences in platelet biology and their relationship with specific cardiovascular events and responses to common antiplatelet therapies. Moreover, as healthy nutrition is widely recognized to play a key role in CVD, we also focused our attention on specific dietary components (especially polyunsaturated fatty acids and flavonoids) and patterns (such as Mediterranean diet), which also emerged to impact platelet functions in a sex-dependent manner. These results highlight that full understanding of gender-related differences will be useful for designing personalized strategies, in order to prevent and/or treat platelet-mediated vascular damage.

In the last two decades, new insights have been gained regarding sex/gender-related differences in cardiovascular disease (CVD). CVD represents the leading cause of death worldwide in both men and women, accounting for at least one-third of all deaths in women and half of deaths in women over 50 years in developing countries. Important sex-related differences in prevalence, presentation, management, and outcomes of different CVDs have been recently discovered, demonstrating sex/gender-specific pathophysiologic features in the presentation and prognosis of CVD in men and women. A large amount of evidence has highlighted the role of sex hormones in protecting women from CVDs, providing an advantage over men that is lost when women reach the menopause stage. This hormonal-dependent shift of sex-related CVD risk consequently affects the overall CVD epidemiology, particularly in light of the increasing trend of population aging. The benefits of physical activity have been recognized for a long time as a powerful preventive approach for both CVD prevention and aging-related morbidity control. Exercise training is indeed a potent physiological stimulus, which reduces primary and secondary cardiovascular events. However, the underlying mechanisms of these positive effects, including from a sex/gender perspective, still need to be fully elucidated. The aim of this work is to provide a review of the evidence linking sex/gender-related differences in CVD, including sex/gender-specific molecular mediators, to explore whether sex- and gender-tailored physical activity may be used as an effective tool to prevent CVD and improve clinical outcomes in women.

• CVD
• clinical outcome
• molecular mediators
• physical activity
• sex/gender differences

• emergency medical services
• epidemiology
• evidence-based medicine
• out-of-hospital cardiac arrest
• resuscitation
• sex and gender

• Endothelial cells
• HUVEC
• Proteome
• Serum starvation
• Sex-specific
• Twins

Identifying biomarkers for the risk of developing degenerative processes linked to aging and colorectal cancer (CRC) onset that could improve clinical strategies.

To determine valid targets and a predictive biomarker’s system of chronicization of inflammation for cancer treatment.

A group of 147 CRC patients was studied. Clinical diagnosis was confirmed histopathologically, and patients were sub-typed using the pathological tumor-node-metastasis classification. Thirteen colon adenoma patients and 219 healthy subjects were also studied. A system biology study on Thioredoxin1/CD30 redox-immune systems (Trx1/CD30), T helper cytokines and polymorphisms of killer immunoglobulin-like receptors, FcγRIIa-131H/R and FcγRIIIa-158V/F was carried out. Enzyme-linked immunosorbent assay was performed to analyze sera. Genetic study was executed by polymerase chain reaction sequence-specific primers and sequence-based typing method. Statistical analysis was performed by using the “Statgraphics software systems”.

We found a positive increase between Trx1/RTrx1 levels and sCD30 level and increased age. With respect to the gender relationships, there were distinct differences. Females showed a primary relationship between transforming growth factor beta (TGFβ) with Trx1, whereas males had one with TGFβ and RTrx1. Trx1/CD30 controls the redox immune homeostasis, and an imbalance in the relationship between the Trx1/RTrx1 and sCD30 levels is linked to the onset and progression of tumor. This event happens through different gender-specific cytokine pathways. Our study demonstrated that the serum levels of Trx1/RTrx1, TGFβ/interleukin (IL)6 and TGFβ/IL4 combinations and the sCD30, IFNγ and IL2 combination constitute a predictive gender specific biomarker system. This is relevant for clinical screening to detect the risk of the potential development or progression of a tumor.

Oxidative stress on Trx1/CD30 is a trigger of cancer disease, and the selected oxidation and immune products are a biomarker system for aging and cancer.

• Aging and cancer biomarker
• Cancer personalized treatments
• Oxidation and immune biomarkers
• Trx1/CD30 target
• KIRs and FcγR polymorphisms
• Th cytokines
• Aging and disease
• Cancer-related mechanisms

• Big data
• Biomarker
• Gender
• Genomics
• Metabolomics
• Personalized medicine
• Precision medicine
• Prevention
• Proteomics
• Sex
• Stratified medicine